BioSpace News Archive

Biotechnology company Antikor Biopharma Ltd is pleased to announce that it has entered into an Investment Agreement for up to US$3,100,000 with Essex Bio-Investment, a wholly-owned subsidiary of Essex Bio-Technology Ltd, which will enable Antikor to consolidate and expand its position as a leading innovator in smaller-format conjugate therapies for solid tumours.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2019.

Centene Corporation announced that its subsidiary Centurion, contracted in Georgia as MHM Correctional Services, LLC, was re-awarded a contract to continue the provision of mental and dental health services to the Georgia Department of Correction’s state prison facilities under a re-awarded contract with the GDC.

Hillrom announced financial results for the fiscal third quarter ended June 30, 2019, and provided its fiscal fourth quarter and updated full-year 2019 financial outlook.

22nd Century Group, Inc. announced that the Company will provide a business update for investors on a conference call to be held Thursday, August 8, 2019, at 4:00 PM.

Deciphera Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2019 and provided an update on clinical and corporate developments.

DexCom, Inc. announced that management will present an update on Dexcom at the following upcoming investor conferences:

The global full-body scanner market is expected to post a CAGR of more than 7% during the period 2019-2023, according to the latest market research report by Technavio.

Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter ended June 30, 2019

SillaJen, Inc., (KOSDAQ:215600), today announced that the Independent Data Monitoring Committee (IDMC) for the company’s PHOCUS trial has evaluated the results of a formal pre-planned futility analysis for this study, and has recommended discontinuation of the trial. The PHOCUS trial is a Phase 3